Literature DB >> 22531343

Syndecan-4 and fibronectin in osteosarcoma.

Ki Yong Na1, Patrizia Bacchini, Franco Bertoni, Youn Wha Kim, Yong-Koo Park.   

Abstract

AIMS: Syndecan-4 (SDC4) and fibronectin (FN), which belong to the cell adhesion molecules, have been reported to correlate with tumour growth and invasion in various carcinomas. We aimed to investigate the prognostic value of these molecules in osteosarcoma.
METHODS: Using immunohistochemistry, we compared the expression of these molecules in high grade osteosarcoma to low grade central osteosarcoma, osteoid osteoma and normal bone. Further, the expression of SDC4 and FN were analysed with prognostic factors of high grade osteosarcoma.
RESULTS: In high grade osteosarcoma, SDC4 was expressed in 50 of the 65 samples; of these, 32 of 65 showed strong expression profiles. FN was expressed in 46 of 65 samples, and 29 of 65 had evidence of strong expression of this molecule. SDC4 and FN expression were increased in high grade osteosarcoma as compared to other tissues. Strong SDC4 expression was associated with the occurrence of distant metastasis and a large tumour size, and strong FN expression was associated with the occurrence of distant metastasis. Strong expression of SDC4 or FN was associated with significantly shorter overall survival, respectively.
CONCLUSIONS: [corrected] Increased expression of SDC4 and FN may be underlying molecular alteration of osteosarcoma which accounts for more aggressive clinical behaviour.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22531343     DOI: 10.1097/PAT.0b013e328353447b

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  15 in total

1.  Pathway-based personalized analysis of cancer.

Authors:  Yotam Drier; Michal Sheffer; Eytan Domany
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-01       Impact factor: 11.205

2.  Extracellular histones are the ligands for the uptake of exosomes and hydroxyapatite-nanoparticles by tumor cells via syndecan-4.

Authors:  Josiah Ochieng; Gladys Nangami; Amos Sakwe; Tanu Rana; Shalonda Ingram; Jeffrey S Goodwin; Cierra Moye; Philip Lammers; Samuel E Adunyah
Journal:  FEBS Lett       Date:  2018-09-20       Impact factor: 4.124

3.  NELL1 Regulates the Matrisome to Promote Osteosarcoma Progression.

Authors:  Qizhi Qin; Mario Gomez-Salazar; Robert J Tower; Leslie Chang; Carol D Morris; Edward F McCarthy; Kang Ting; Xinli Zhang; Aaron W James
Journal:  Cancer Res       Date:  2022-08-03       Impact factor: 13.312

4.  Sarcoma Tumor Microenvironment.

Authors:  Panagiotis Tsagozis; Jordi Gonzalez-Molina; Anna-Maria Georgoudaki; Kaisa Lehti; Joseph Carlson; Andreas Lundqvist; Felix Haglund; Monika Ehnman
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

5.  Acquisition of anoikis resistance up-regulates syndecan-4 expression in endothelial cells.

Authors:  Bruna Ribeiro Carneiro; Paulo Castanho A Pernambuco Filho; Ana Paula de Sousa Mesquita; Douglas Santos da Silva; Maria Aparecida S Pinhal; Helena B Nader; Carla Cristina Lopes
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

6.  Syndecan-4 negatively regulates antiviral signalling by mediating RIG-I deubiquitination via CYLD.

Authors:  Wei Lin; Jing Zhang; Haiyan Lin; Zexing Li; Xiaofeng Sun; Di Xin; Meng Yang; Liwei Sun; Lin Li; Hongmei Wang; Dahua Chen; Qinmiao Sun
Journal:  Nat Commun       Date:  2016-06-09       Impact factor: 14.919

7.  Dioscin Inhibits HSC-T6 Cell Migration via Adjusting SDC-4 Expression: Insights from iTRAQ-Based Quantitative Proteomics.

Authors:  Lianhong Yin; Yan Qi; Youwei Xu; Lina Xu; Xu Han; Xufeng Tao; Shasha Song; Jinyong Peng
Journal:  Front Pharmacol       Date:  2017-09-20       Impact factor: 5.810

8.  Killing two birds with one stone: dual blockade of integrin and FGF signaling through targeting syndecan-4 in postoperative capsular opacification.

Authors:  Yingyan Qin; Yi Zhu; Furong Luo; Chuan Chen; Xiaoyun Chen; Mingxing Wu
Journal:  Cell Death Dis       Date:  2017-07-13       Impact factor: 8.469

9.  Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma.

Authors:  Kai Shi; Sheng-Lin Wang; Bin Shen; Feng-Qiang Yu; Dan-Feng Weng; Jian-Hua Lin
Journal:  World J Surg Oncol       Date:  2019-01-28       Impact factor: 2.754

Review 10.  Syndecans as modulators and potential pharmacological targets in cancer progression.

Authors:  Despoina Barbouri; Nikolaos Afratis; Chrisostomi Gialeli; Demitrios H Vynios; Achilleas D Theocharis; Nikos K Karamanos
Journal:  Front Oncol       Date:  2014-02-03       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.